Preventing Thrombosis After the Fontan Procedure Not There Yet⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. by Canter, Charles E.
Journal of the American College of Cardiology Vol. 58, No. 6, 2011
© 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.062EDITORIAL COMMENT
Preventing Thrombosis
After the Fontan Procedure
Not There Yet*
Charles E. Canter, MD
St. Louis, Missouri
In 2007 (1), a review of the experience with thromboem-
bolism and use of anticoagulation after the Fontan proce-
dure in patients with single-ventricle lesions came to 4
conclusions: 1) thromboembolic events occur both early and
late after the Fontan procedure at a frequency higher than
any other cardiac surgery in children other than prosthetic
valve replacement; 2) these thromboembolic events contrib-
ute to the failure of Fontan physiology and their occurrence
increases in a “failed Fontan”; 3) these thromboembolic
events occur in the presence of absence of standard antico-
agulation schemes, including combinations of heparin and
warfarin; and 4) the factors predisposing to thromboembo-
lism after the Fontan procedure likely represented a complex
interaction of multiple factors. They speculated that it
would be unlikely that any single anticoagulation agent
would provide a solution to such a complex problem.
See page 645
In this issue of the Journal, Monagle et al. (2) present the
findings of a study that would appear to confirm this
opinion. Their study began as an ambitious randomized trial
comparing a regimen of acetylsalicylic acid (ASA) with
post-operative heparin followed by oral warfarin therapy to
prevent thromboembolism in children undergoing the Fon-
tan procedure. In addition to perspective randomization of
patients to ASA or heparin/warfarin, the study’s primary
endpoint was innovative because it included both thrombus
that led to clinical events and the presence of asymptomatic
or silent thromboemboli that were detected by transesoph-
ageal echocardiography (TEE), a relatively invasive proce-
dure not usually in done in the routine clinical management
of Fontan patients.
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consultant for Blue Cross Blue Shield and Optum Health.Unfortunately, the execution of the study fell short of its
initial intent. The targeted recruitment goal was 242 pa-
tients to attain statistical power. Only 111 patients were
eventually enrolled. Although 81% of the population un-
derwent at least 1 surveillance TEE, only 48% of the
subjects had both surveillance TEEs; thus, the true preva-
lence of silent thromboemboli was not fully ascertained. The
numbers of silent and clinically evident thromboemboli
were nearly identical in the ASA and heparin/warfarin
groups. However, the sample size is too small to confirm
noninferiority of either therapy as the possible differences
between ASA and heparin/warfarin therapies range from
ASA therapy conferring a 1.6 times greater risk of throm-
boembolism compared with heparin/warfarin and heparin/
warfarin conferring a 3 times greater risk than ASA.
Although this study did not accomplish its initial purpose
as a clinical trial, it does offer important data in its final form
as 3 large multicenter observational studies rolled into one:
1) a large prospective intention-to-treat study of ASA
prophylaxis after the Fontan procedure; 2) a similar
intention-to-treat study for heparin/warfarin prophylaxis in
Fontan patients; and 3) an assessment of TEE as a means
for surveillance for thromboembolism in Fontan patients.
The study confirms results from a contemporary Fontan
experience (3) demonstrating the rate of clinical events
associated with thromboemboli in the first years after the
Fontan procedure to be low. In the current study (2),
symptoms from a clot in the Fontan connection developed
in only 3 of the 111 patients. The rest of the clinically
detected thrombi were in the femoral (n  3) and jugular
(n 1) veins where previous cardiac catheterization and/or the
placement of central intravenous lines may have also influenced
thrombus formation. This study also confirms another recent
experience (4) demonstrating a low, clinically evident preva-
lence of thromboemboli using ASA as prophylaxis.
The study clearly illustrates the challenges of using
warfarin as prophylactic therapy in children. Nearly one-
fifth of the patients started on warfarin stopped the drug
before the end of the study. Forty-one percent of interna-
tional normalized ratio measurements were below the rec-
ommended therapeutic range. Poor compliance with war-
farin therapy (patients who had 30% of international
normalized ratio measurements in the therapeutic range)
had a significant greater risk of thrombosis. Thus, even
discounting the extra need for performing periodic blood
testing with warfarin therapy, “maintenance” of anticoagu-
lation with warfarin was suboptimal and frequently erratic.
This study also confirmed findings from previous expe-
rience (5) that surveillance TEE frequently detects emboli
without clinical symptoms and/or not seen on standard
transthoracic echocardiography. In all cases, the intensity of
anticoagulation was increased and no clinical events oc-
curred. However, it appears that routine periodic TEE
surveillance was difficult because only one-half of the
subjects had 2 TEE studies.
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Fontan survivors identified thromboembolism as an impor-
tant continuing cause of mortality in this patient group and
that no anticoagulation therapy confers a substantial risk
(hazard ratio: 90) for thromboembolic death. Another
study (7) found a higher rate of thromboembolic events in
patients not treated with anticoagulation compared with
treatment with ASA or warfarin. Thus, it is unlikely that
most clinicians would not attempt some form of anticoag-
ulation therapy in patients after the Fontan procedure.
Monagle et al. have provided evidence that currently used
therapies are not as effective as we would like them to be.
However, their experience also suggests that primary pre-
vention antithrombotic strategies using recurrent invasive
surveillance must be associated with a high enough benefit/
risk and/or inconvenience ratio to gain acceptance by
patients and their families.
Optimal strategies to reduce mortality and morbidity
with thromboembolism after the Fontan procedure clearly
remain to be determined. It is likely that the newer
anticoagulants undergoing evaluation in adults with atrial
fibrillation (8) will be tested in Fontan patients. Antithrom-
botic strategies should also not be limited to primary
prophylaxis. Screening for hereditary thrombophilia before
surgery may be helpful. Care needs to be taken to avoid
creation of areas of stagnant flow such as pulmonary artery
stumps (9) or ascending aortas in aortic atresia (10) that
predispose to arterial thrombi and stroke. Individualization
of antithrombotic strategies for patients who demonstrate
prothrombotic states such as increased levels of factor VIII
(11) may be efficacious. As patients who underwent the
Fontan procedure age, and complications develop such as
ventricular systolic dysfunction, atrial arrhythmias, and
chronic lower extremity venous insufficiency (12) that in-
crease the risk of thromboembolic events, the surveillance
and therapy to prevent such events should become more
intense and aggressive. Ultimately, tailored antithrombotic
therapy for individual Fontan patients as they age will likely
be more effective than a “one-size-fits-all” approach.Reprint requests and correspondence: Dr. Charles E. Canter,
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